Is erythromycin therapy teratogenic in humans?
(2005) In Reproductive Toxicology 20(2). p.209-214- Abstract
- The possible teratogenic effect of erythromycin therapy, noted previously, was studied. Women who had taken erythromycin or penicillin V in early pregnancy and their infants were studied, using the Swedish Medical Birth Register where information on drug use during pregnancy was recorded based on interviews in early pregnancy. The risk for any congenital malformation after erythromycin therapy (but not after penicillin V therapy) was increased (odds ratio 1.24, 95% confidence interval: 1.01-1.51) and this was due to an effect on cardiovascular malformations (odds ratio 1.92, 95% CI: 1.37-2.68). There was also an indicated increased risk for pyloric stenosis (risk ratio 3.0, 95% CI: 1.1-8.5 after exposure in early pregnancy). Various... (More)
- The possible teratogenic effect of erythromycin therapy, noted previously, was studied. Women who had taken erythromycin or penicillin V in early pregnancy and their infants were studied, using the Swedish Medical Birth Register where information on drug use during pregnancy was recorded based on interviews in early pregnancy. The risk for any congenital malformation after erythromycin therapy (but not after penicillin V therapy) was increased (odds ratio 1.24, 95% confidence interval: 1.01-1.51) and this was due to an effect on cardiovascular malformations (odds ratio 1.92, 95% CI: 1.37-2.68). There was also an indicated increased risk for pyloric stenosis (risk ratio 3.0, 95% CI: 1.1-8.5 after exposure in early pregnancy). Various explanations to the finding are discussed, one of them linked to the fact that erythromycin inhibits a specific cardiac potassium channel (IKr) which seems to play a major role in cardiac rhythm regulation in the early embryo. Potent blocking drugs cause as a class effect cardiac defects in animal experiments. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/236388
- author
- Källén, Bengt LU ; Olausson, PO and Danielsson, BR
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- epidemiology, pyloric stenosis, cardiovascular defects, erythromycin, teratogenicity, IKr, hERG
- in
- Reproductive Toxicology
- volume
- 20
- issue
- 2
- pages
- 209 - 214
- publisher
- Elsevier
- external identifiers
-
- wos:000229647200005
- scopus:19444367335
- pmid:15907655
- ISSN
- 1873-1708
- DOI
- 10.1016/j.reprotox.2005.01.010
- language
- English
- LU publication?
- yes
- id
- 94f13813-2d64-4b48-a3bd-1b813563863c (old id 236388)
- date added to LUP
- 2016-04-01 16:37:20
- date last changed
- 2022-02-27 22:28:42
@article{94f13813-2d64-4b48-a3bd-1b813563863c,
abstract = {{The possible teratogenic effect of erythromycin therapy, noted previously, was studied. Women who had taken erythromycin or penicillin V in early pregnancy and their infants were studied, using the Swedish Medical Birth Register where information on drug use during pregnancy was recorded based on interviews in early pregnancy. The risk for any congenital malformation after erythromycin therapy (but not after penicillin V therapy) was increased (odds ratio 1.24, 95% confidence interval: 1.01-1.51) and this was due to an effect on cardiovascular malformations (odds ratio 1.92, 95% CI: 1.37-2.68). There was also an indicated increased risk for pyloric stenosis (risk ratio 3.0, 95% CI: 1.1-8.5 after exposure in early pregnancy). Various explanations to the finding are discussed, one of them linked to the fact that erythromycin inhibits a specific cardiac potassium channel (IKr) which seems to play a major role in cardiac rhythm regulation in the early embryo. Potent blocking drugs cause as a class effect cardiac defects in animal experiments.}},
author = {{Källén, Bengt and Olausson, PO and Danielsson, BR}},
issn = {{1873-1708}},
keywords = {{epidemiology; pyloric stenosis; cardiovascular defects; erythromycin; teratogenicity; IKr; hERG}},
language = {{eng}},
number = {{2}},
pages = {{209--214}},
publisher = {{Elsevier}},
series = {{Reproductive Toxicology}},
title = {{Is erythromycin therapy teratogenic in humans?}},
url = {{http://dx.doi.org/10.1016/j.reprotox.2005.01.010}},
doi = {{10.1016/j.reprotox.2005.01.010}},
volume = {{20}},
year = {{2005}},
}